Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies

Detalles Bibliográficos
Autores principales: De Giglio, Andrea, Nuvola, Giacomo, Dall’Olio, Filippo Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798162/
https://www.ncbi.nlm.nih.gov/pubmed/35117058
http://dx.doi.org/10.21037/tcr.2019.12.69
_version_ 1784641733996314624
author De Giglio, Andrea
Nuvola, Giacomo
Dall’Olio, Filippo Gustavo
author_facet De Giglio, Andrea
Nuvola, Giacomo
Dall’Olio, Filippo Gustavo
author_sort De Giglio, Andrea
collection PubMed
description
format Online
Article
Text
id pubmed-8798162
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87981622022-02-02 Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies De Giglio, Andrea Nuvola, Giacomo Dall’Olio, Filippo Gustavo Transl Cancer Res Editorial Commentary AME Publishing Company 2019-12 /pmc/articles/PMC8798162/ /pubmed/35117058 http://dx.doi.org/10.21037/tcr.2019.12.69 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
De Giglio, Andrea
Nuvola, Giacomo
Dall’Olio, Filippo Gustavo
Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
title Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
title_full Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
title_fullStr Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
title_full_unstemmed Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
title_short Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
title_sort carboplatin, nab-paclitaxel plus atezolizumab in impower 130 trial: new weapons beyond controversies
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798162/
https://www.ncbi.nlm.nih.gov/pubmed/35117058
http://dx.doi.org/10.21037/tcr.2019.12.69
work_keys_str_mv AT degiglioandrea carboplatinnabpaclitaxelplusatezolizumabinimpower130trialnewweaponsbeyondcontroversies
AT nuvolagiacomo carboplatinnabpaclitaxelplusatezolizumabinimpower130trialnewweaponsbeyondcontroversies
AT dalloliofilippogustavo carboplatinnabpaclitaxelplusatezolizumabinimpower130trialnewweaponsbeyondcontroversies

Ejemplares similares